Collaborations & Alliances
Related Searches:
Filter by:
October 17, 2007
ImClone and Bristol-Myers Squibb have established an agreement with Merck KgA to co-develop and co-commercialize Erbitux in Japan. The three companies will collaborate on a joint effort to develop and, following regulatory approval, market the drug i…
Read More »
October 16, 2007
Genentech has initiated an expansion cohort in Phase I trial of a Hedgehog antagonist, triggering a $3 million cash payment to Curis, Inc. under the companies' June 2003 collaboration agreement. The Phase I trial expansion satisfies the criteria for…
Read More »
October 11, 2007
Akorn, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for the development of an ANDA oral drug product for women's healthcare. Financial terms of the agreement were not disclosed.
Sofgen will…
Read More »
October 10, 2007
GlaxoSmithKline and Synta Pharmaceuticals Corp. have entered a global collaboration for the development and commercialization of STA-4783, a small-molecule oxidative stress inducer in Phase III development for the treatment of metastatic melanoma.…
Read More »
October 10, 2007
Zealand Pharma received an undisclosed milestone payment from Wyeth for the advancement of an orally available gap junction modifier ZP1609 (GAP-134) into Phase I trials in the U.S.
This is the second gap junction modifier in clinical trials dev…
Read More »
October 5, 2007
AMRI and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) entered a four-year research collaboration aimed at identifying novel treatments that address the core defect in cystic fibrosis. Under the collaboration, CFFT will commit as much as $23.…
Read More »
October 4, 2007
Targeted Genetics Corp. received an undisclosed milestone payment from Amsterdam Molecular Therapeutics B.V. (AMT) under a licensing agreement that provides AMT with non-exclusive rights to Adeno-Associated Virus type 1 (AAV1), a serotype of AAV with…
Read More »
October 2, 2007
Isis Pharmaceuticals, Inc. earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase I trial of ISIS 325568.
The collaboration, announced in Septembe…
Read More »
September 28, 2007
Celera, an Applera Corp. business, earned a $2 million clinical milestone payment from Merck & Co. under the two companies cathepsin K inhibitor collaboration agreement.
This payment recognizes Merck's advancement of odanacatib (formerly MK-…
Read More »
September 27, 2007
Galapagos NV and ProStrakan Group achieved the third milestone under Galapagos' collaboration with Novartis in antibodies for bone-related diseases. This milestone triggers a payment of $1.5 million to Galapagos, of which Galapagos will pay $1.1 mill…
Read More »
September 24, 2007
Array BioPharma and Celgene Corp. entered a strategic R&D collaboration focused on novel therapeutics in cancer and inflammation. Under the agreement, Array will receive an upfront payment of $40 million and will grant Celgene an option to select…
Read More »
September 21, 2007
Exelixis, Inc. has signed an extension of its research collaboration with Bristol-Myers Squibb Co. to develop and commercialize therapies targeted against the Liver X Receptor (LXR), a hormone receptor associated with a variety of cardiovascular and…
Read More »
September 17, 2007
Celera has entered into a research collaboration with Merck to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate certain gene expression profiles identified by Merck with the goal…
Read More »
September 7, 2007
Pozen, Inc. and AstraZeneca began the Phase III program for PN 400, a fixed dose combination of the proton pump inhibitor (PPI), esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet. An NDA is tar…
Read More »
September 7, 2007
Patheon
3Q Revenues: $175.5 million (-2%)
3Q Loss: $63.1 million (loss of $257.2 million in 3Q2006)
YTD Revenues: $510.3 million (flat)
YTD Loss: $87.1 million (loss of $265.7 million YTD2006)
Comments: Rx manufacturing revenues i…
Read More »
